ChromoCure, Inc will be starting clinical testing and trials for its landmark ChromoSomal Scanning Technology as applied to cervical cancer soon. These clinical testing and trials are anticipated to be the first in a series relating to the different forms of cancer. The Cervical Clinical Trials will apply the Company's detection technology to standard "Pap Smear" slides in order to demonstrate the effectiveness of detection and the specificity of the scan. The clinical trial phase-1 is expected to be completed by 15 April 2011. At which time, the company will apply for regulatory approval for Europe-wide permission to introduce the company's systems and technology to participating laboratories.

The clinics and laboratories participating in the trial will be announced immediately subsequent to the July 15, 2010 planned commencement date. Preliminary data of the phase-1 Trial are expected to be published on or about 15 December 2010.

The company's cancer detection technology is based on the chromosomal theory of cancer. Research has conclusively and irrefutably demonstrated aneuploidy a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. The company's cancer detection system locates and measures unique genomic characteristic found in 100 per cent of all cancers and never found in normal cells. The company's detection technology has an effective 100 per cent accuracy rate and an effective 100 per cent specificity therefore making "false positives" and "false negatives" theoretically impossible.

The company possesses advanced detection and therapeutic technology and protocols, comprised of ChromoCure's advanced detection system and GRG's full line of therapeutic protocols and technology; allowing for the first time real-time progression monitoring and remission detection -- providing the world's first cure research fully integrated system for the precise measurement of treatment and on-demand, real-time cancer progression analysis to monitor and determine treatment efficacy.

The company's recently announced merger with GRG will be of mutual benefit in advancement of their shared objective; as a focused Cancer Therapy and Cure Research & Development organization. The announced merger and acquisition of GRG prepares the group for a leading role in this new era of cancer research, detection and therapy.

The combined entity possesses complementary detection and therapeutic technology and protocols. Management believes the transaction to be of significant long-term shareholder value and furthers the Company's transition to research, technology development, and licensing as a source of significant long-term and recurring revenues and equity appreciation.

The company's focus on cancer research is further underscored by recent major clinical publications that both validate ChromoCure's chromosomal/aneuploidy theory of cancer and establish the company's detection approach as the forefront of both cancer detection and research. The Mayo Clinic's recent landmark findings confirming aneuploidy as the cause of cancer were published in the December 2009 Cancer Cell journal. This publication has spurred increased worldwide research by a number of respected research universities and institutions, all of which have published similar reports in 2010.

This announcement, together with the recently announced the Euro Zone launch of its Pathologist Collaborative Research (PCR) Programme in support of the groundbreaking Project Boveri: Find the Cure Initiative, further establish the company's leading role in the new era of cancer research, detection, and therapy, as the companies leverage their combined technologies, research knowledge and industry relationships.

The company develops and provides proprietary cancer detection systems and related therapeutic technologies.